Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
Cryz
S J
SJ
Swiss Serum and Vaccine Institute, Berne, Switzerland.
Sadoff
J C
JC
Cross
A S
AS
Fürer
E
E
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000917:Antibody Formation; D001427:Bacterial Toxins / Q000276:immunology* / Q000633:toxicity; D001428:Bacterial Vaccines / Q000276:immunology* / Q000633:toxicity; D002056:Burns / Q000150:complications; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007928:Lethal Dose 50; D051379:Mice; D011135:Polysaccharides, Bacterial / Q000276:immunology* / Q000633:toxicity; D054406:Pseudomonas Vaccines; D011550:Pseudomonas aeruginosa / Q000276:immunology* / Q000378:metabolism
D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial; D054406:Pseudomonas Vaccines; C060069:Pseudomonas aeruginosa O polysaccharide-toxin A conjugate vaccine